Manasi Bhavsar

Dr. Manasi Bhavsar

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2019 in Indian Journal of Clinical Biochemistry
Verified
Journal Article
Closed access
PDF file
JJJigna Joshi
Jigna Joshi
ARApexa Raval
Apexa Raval
UDUrja Desai
Urja Desai
VUVinal Upadhyay
Vinal Upadhyay
MBManasi Bhavsar
Manasi Bhavsar
FSFranky Shah
Franky Shah

30 June 2023 in Advances in Cancer Biology - Metastasis
Verified
Journal Article
Open access
MBManasi Bhavsar
Manasi Bhavsar
NMNaman Mangukia
Naman Mangukia
SKSivakumar Prasanth Kumar
Sivakumar Prasanth Kumar
SPSaumya Patel
Saumya Patel
RRRakesh M. Rawal
Rakesh M. Rawal
AMArchana Mankad
Archana Mankad

28 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
NJNour Abu jayab
Nour Abu jayab
Burcu Yener IlceBurcu Yener Ilce
Burcu Yener Ilce
Reem S AlhamidiReem S Alhamidi
Reem S Alhamidi
MBManasi Bhavsar
Manasi Bhavsar
AAAlaa Altaie
Alaa Altaie
Rifat HamoudiRifat Hamoudi
Rifat Hamoudi
Background: A20, encoded by tumor necrosis factor alpha-induced protein 3 (TNFAIP3), is a key negative regulator of NF-κB signaling with context-dependent functions in cancer. Its role in renal cell carcinoma (RCC), particularly clear-cell RCC (ccRCC), remains incompletely defined. Methods: Public GEO transcriptomic data from 23 controls and 32 ccRCC samples were analyzed using gene set enrichment analysis (GSEA). A20-overexpressing HEK293 and 786-O cells were assessed by functional assays and transcriptomic profiling. Eight ccRCC FFPE samples were profiled to compare A20-associated transcriptional patterns with cell-line data. Targeted DNA sequencing was performed in 11 ccRCC and 8 papillary RCC samples, and whole-exome sequencing was conducted in A20-overexpressing 786-O cells. Key genes were further evaluated using Kaplan-Meier survival analysis in 530 ccRCC patients and TCGA-KIRC data comprising 533 primary tumors and 72 normal samples. Results: GEO analysis showed significant TNFAIP3/A20 upregulation in ccRCC (p = 3.96 × 10−5) and enrichment of NF-κB-related gene sets (p = 0.01). A20 overexpression produced distinct phenotypes in HEK293 and 786-O cells. In HEK293 cells, A20 increased BIK and ARHGAP6 expression and was associated with increased apoptosis and reduced wound closure. In 786-O cells, A20 suppressed ARHGAP6 and APAF1 and was associated with increased proliferation, enhanced wound closure, and reduced apoptosis relative to EV controls. A20-high ccRCC samples showed enrichment of NF-κB, TGF-β, DNA repair, mTOR/metabolic, hypoxia, and proteasome-related pathways. Genomic analyses identified alterations in NF-κB-related genes, including CARD10 and IRAK1. Conclusions: A20/TNFAIP3 may exert cell-context-dependent effects in RCC and is associated with tumor-relevant transcriptional and genomic alterations requiring further validation.